GCL Global's fiscal first-half revenue nearly doubled after consolidating Ban Leong Technologies, yet the company reported a net loss as it absorbed acquisition costs. Management lowered full-year guidance, citing delays for two key game titles.
Indian e-commerce challenger Meesho reported a significant widening of its quarterly net loss to ₹4.91 billion, as a 44% surge in expenses outpaced strong revenue growth, marking a costly start to its life as a public company.
Tesla maintained its Bitcoin position through a turbulent quarter, reporting significant unrealized losses as cryptocurrency markets slumped, even as its core automotive business outperformed expectations.
While Sligro Food Group (AMS:SLIGR) shares have seen a modest 11% rebound in recent months, long-term investors are nursing significant losses, with the stock down 46% over five years. This deep dive examines the disconnect between the company's path to profitability and its languishing share price.
SL Green Realty Corp. posted a significant net loss for 2025 despite rising revenues and robust leasing activity. The Manhattan office landlord confirmed a shift to quarterly dividends and is advancing major financing and asset sale plans, placing cash conservation and balance sheet flexibility at the forefront of its recovery strategy.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
A 40-year-old New Yorker, grieving the loss of both parents, has inherited $400,000. Now, as she plans to marry, buy a home, and start a family, she wrestles with the emotional and financial weight of using that legacy to build her new life.
Despite a modest rise in annual revenue, Mudajaya Group Berhad (KLSE:MUDAJYA) has seen its share price plummet 65% over five years, leaving long-term investors deep in the red. We examine the disconnect between business performance and market sentiment.
The pharmaceutical giant is set to release quarterly results before the bell Wednesday, with Wall Street anticipating another period of blockbuster revenue growth driven by its GLP-1 drugs.
Peloton Interactive announces a major restructuring, cutting jobs primarily in tech and corporate roles as new CEO Peter Stern prioritizes cash flow and operational efficiency over expansion, amid a prolonged stock slump and intense competition.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
The death of a spouse brings profound emotional and financial changes. This guide outlines key steps to reassess benefits, taxes, and income strategies to secure long-term stability during a difficult transition.
Silver prices experienced a dramatic and historic sell-off on Friday, tumbling over 30% as a surging U.S. dollar and political uncertainty rattled markets. Analysts caution the downturn may not be over, with one prominent forewarning of a potential slide to $68 an ounce.
Pharmaceutical giant Eli Lilly is investing $3.5 billion to build a new manufacturing facility in rural Pennsylvania, marking its latest move in a massive U.S. expansion aimed at meeting soaring demand for next-generation obesity treatments and capitalizing on reshoring incentives.
Wheat markets opened the week under pressure, with futures across Chicago, Kansas City, and Minneapolis exchanges trading lower. A stronger U.S. dollar and mixed fundamental data, including a key Taiwanese purchase, set the tone for a cautious start.
Investors in lighting specialist FW Thorpe have seen a negative total shareholder return of 25% since 2021, starkly underperforming the broader market's gains. Despite steady revenue growth, the share price decline highlights a disconnect with company fundamentals.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Justice Secretary David Lammy's proposal to redirect interest from law firms' client accounts to fund the justice system could jeopardize up to 6,500 jobs, according to industry analysis, raising alarms about the financial stability of the sector.
